Cetus Healthcare Limited Partnership II
Public offering of shares in the $100 mil. R&D partnership began Oct. 30. Proceeds will be used to fund the development of therapeutic products in Europe through the company's new subsidiary, EuroCetus ("The Pink Sheet" Aug. 25, T&G-2). Shearson Lehman Brothers and Oppenheimer are managing the sale.
You may also be interested in...
A trio of newly finalized guidance documents from the US agency dated 25 September explain how the Accreditation Scheme for Conformity Assessment pilot will work, and what biocompatibility and safety standards will apply.
Approval of Alaway Preservative Free (ketotifen fumarate, 0.035) comes 15 months after FDA submitted a complete response letter to Bausch and the active ingredient developer, Eton Pharmaceuticals.
Unfounded expectation some firms have for FDA to protect their investments in preparing successful NDI notifications is part of industry’s overall interest in increased regulation of the market, says Steven Tave, Office of Dietary Supplement Programs director.